Effectiveness of a community health worker-led low-sodium salt intervention to reduce blood pressure in rural Bangladesh: protocol for a cluster randomized controlled trial.
Bangladesh
Blood pressure
Community health worker
Global health
Hypertension
Low-sodium salt substitute
Sodium
South Asia
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
27 Jul 2023
27 Jul 2023
Historique:
received:
27
03
2023
accepted:
17
07
2023
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
27
7
2023
Statut:
epublish
Résumé
High blood pressure is a major public health problem in low- and middle-income countries. Low-sodium salt substitute (LSSS) is a promising population-level blood pressure-lowering intervention requiring minimal behavioral change. The optimal method of delivering LSSS to individuals, however, is currently unknown. Community health workers (CHWs) have successfully been used to implement health interventions in Bangladesh and may provide a venue for the dissemination of LSSS. We aim to conduct a cluster-randomized controlled trial involving 309 households in rural Bangladesh previously identified and characterized by the BRAC James P Grant School of Public Health, BRAC University (BRAC JPGSPH). These households will be randomly assigned to three arms: (1) control, i.e., no intervention; (2) information only, i.e., community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire); (3) free LSSS arm: the same information as in arm 2 will be provided, but participants will receive 6 months of free low-sodium salt along with education on the benefits of LSSS. One male and one female adult (age ≥ 18 years) in each household will be invited to participate, the exclusion criteria being households with members known to have high serum potassium levels, are taking medications known to elevate potassium levels (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics), are already taking potassium supplements, or those who have known kidney disease or abnormal serum creatinine at baseline. The primary endpoint will be blood pressure at 6 months post-intervention. Recent large clinical trials of LSSS in China and India have shown not only blood pressure improvements, but also stroke, major cardiac event, and all-cause mortality reductions. Nevertheless, how to best translate this intervention to population-level effectiveness remains unclear. Our study would test whether a community health worker-based program could be effectively used to disseminate LSSS and achieve measurable blood pressure benefits. ClinicalTrials.gov NCT05425030. Registered on June 21, 2022.
Sections du résumé
BACKGROUND
BACKGROUND
High blood pressure is a major public health problem in low- and middle-income countries. Low-sodium salt substitute (LSSS) is a promising population-level blood pressure-lowering intervention requiring minimal behavioral change. The optimal method of delivering LSSS to individuals, however, is currently unknown. Community health workers (CHWs) have successfully been used to implement health interventions in Bangladesh and may provide a venue for the dissemination of LSSS.
METHODS
METHODS
We aim to conduct a cluster-randomized controlled trial involving 309 households in rural Bangladesh previously identified and characterized by the BRAC James P Grant School of Public Health, BRAC University (BRAC JPGSPH). These households will be randomly assigned to three arms: (1) control, i.e., no intervention; (2) information only, i.e., community health workers will provide basic information on high blood pressure, the health consequences of excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire); (3) free LSSS arm: the same information as in arm 2 will be provided, but participants will receive 6 months of free low-sodium salt along with education on the benefits of LSSS. One male and one female adult (age ≥ 18 years) in each household will be invited to participate, the exclusion criteria being households with members known to have high serum potassium levels, are taking medications known to elevate potassium levels (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics), are already taking potassium supplements, or those who have known kidney disease or abnormal serum creatinine at baseline. The primary endpoint will be blood pressure at 6 months post-intervention.
DISCUSSION
CONCLUSIONS
Recent large clinical trials of LSSS in China and India have shown not only blood pressure improvements, but also stroke, major cardiac event, and all-cause mortality reductions. Nevertheless, how to best translate this intervention to population-level effectiveness remains unclear. Our study would test whether a community health worker-based program could be effectively used to disseminate LSSS and achieve measurable blood pressure benefits.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05425030. Registered on June 21, 2022.
Identifiants
pubmed: 37501102
doi: 10.1186/s13063-023-07518-3
pii: 10.1186/s13063-023-07518-3
pmc: PMC10375753
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Sodium Chloride, Dietary
0
Sodium
9NEZ333N27
Banques de données
ClinicalTrials.gov
['NCT05425030']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
480Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2020 Mar 7;395(10226):795-808
pubmed: 31492503
J Cardiovasc Nurs. 2014 Jul;29(4):308-14
pubmed: 23635809
Int J Epidemiol. 2017 Oct 1;46(5):1421-1432
pubmed: 28582528
BMC Nephrol. 2018 Oct 23;19(1):291
pubmed: 30352554
Am J Clin Nutr. 2021 Jul 1;114(1):185-193
pubmed: 33782684
J Hum Hypertens. 2013 Jul;27(7):427-33
pubmed: 23254595
Diabetes Care. 2018 May;41(5):963-970
pubmed: 29475843
J Hypertens. 2007 Oct;25(10):2011-8
pubmed: 17885542
Nutrients. 2021 Jan 19;13(1):
pubmed: 33477824
PLoS One. 2015 Jul 30;10(7):e0134700
pubmed: 26225848
Zhonghua Yu Fang Yi Xue Za Zhi. 2003 Mar;37(2):90-2
pubmed: 12839657
Arq Bras Cardiol. 2015 Feb;104(2):128-35
pubmed: 25409877
Br J Nutr. 2009 Apr;101(7):1088-93
pubmed: 18710605
Lancet. 2018 Mar 24;391(10126):1224-1236
pubmed: 29108723
Lancet. 2013 Jul 27;382(9889):363-5
pubmed: 23541538
Nestle Nutr Workshop Ser Pediatr Program. 2009;63:1-10; discussion 10-4, 259-68
pubmed: 19346763
Medicine (Baltimore). 2018 Apr;97(14):e0342
pubmed: 29620663
PLoS One. 2014 Oct 22;9(10):e110131
pubmed: 25338053
Health Psychol Rev. 2017 Jun;11(2):145-163
pubmed: 28281891
PLoS One. 2017 Jul 13;12(7):e0180640
pubmed: 28704405
Lancet. 2019 Aug 24;394(10199):652-662
pubmed: 31327566
Int J Cardiol. 2016 Jul 15;215:377-82
pubmed: 27128565
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
Nat Med. 2020 Mar;26(3):374-378
pubmed: 32066973
Clin Hypertens. 2016 Oct 17;22:18
pubmed: 28031983
PLoS One. 2016 Dec 9;11(12):e0166620
pubmed: 27935977
Lancet Diabetes Endocrinol. 2018 Sep;6(9):681-683
pubmed: 29371077
Int J Epidemiol. 2021 Jul 9;50(3):717-718e
pubmed: 34143882
N Engl J Med. 2021 Sep 16;385(12):1067-1077
pubmed: 34459569
Bull World Health Organ. 2002;80(6):445-50
pubmed: 12132000
Eur Heart J. 2020 Sep 14;41(35):3363-3373
pubmed: 33011774
JAMA Netw Open. 2019 Dec 2;2(12):e1916545
pubmed: 31790570
Am J Hypertens. 2009 Sep;22(9):934-42
pubmed: 19661926
Lancet. 2017 Jan 7;389(10064):37-55
pubmed: 27863813